25D-NBOMe

1. 2026-10-19issueIssued emergency
2. 2026-10-19issueIssued info_card
3. 2026-10-19issueIssued notice
4. 2026-09-07srcAnalytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs.
5. 2026-09-07src25C-NBOMe and 25I-NBOMe metabolite studies in human hepatocytes, in vivo mouse and human urine with high-resolution mass spectrometry
6. 2026-09-07srcPharmacology and Toxicology of N-Benzylphenethylamine (NBOMe) Hallucinogens
7. 2026-09-07srcDesigner drugs: mechanism of action and adverse effects
8. 2026-09-07srcBehavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function
9. 2026-09-07srcMetabolic profile determination of 25N-NBOMe in human liver microsomes by liquid chromatography-quadrupole time-of-flight mass spectrometry
10. 2026-09-07srcNeurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.
11. 2026-09-07src25I-NBOMe related death in Australia: a case report
12. 2026-09-07srcA fatal poisoning involving 25C-NBOMe.
13. 2026-09-07srcDeath after 25C-NBOMe and 25H-NBOMe consumption.
14. 2026-09-07srcMetabolic fate and detectability of 25B-NBOMe and 25C-NBOMe in human and rat urine by GC-MS, LC-MSn, and LC-HR-MS/MS approaches.
15. 2026-09-07srcReceptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs)
16. 2026-09-07src2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo
17. 2026-09-07srcDesigner Drug, 25D-NBOMe, Has Reinforcing and Rewarding Effects through Change of a Dopaminergic Neurochemical System
18. 2026-09-07srcIdentification of 5-HT2A receptor signaling pathways associated with psychedelic potential
19. 2026-09-07src25X-NBOMe compounds - chemistry, pharmacology and toxicology. A comprehensive review.
20. 2026-09-07srcHigh-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens
21. 2026-09-07srcFatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014.
22. 2026-09-07srcHow to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings
23. 2026-09-07srcNBOMes-Highly Potent and Toxic Alternatives of LSD
24. 2026-09-07srcMolecular and Medical Aspects of Psychedelics.
25. 2026-09-07srcMechanistic Insights into the Neurotoxicity of 2,5-Dimethoxyphenethylamines (2C) and Corresponding N-(2-methoxybenzyl)phenethylamine (NBOMe) Drugs
26. 2026-09-07src25D-NBOMe Experience Report: 'Almost but Not Quite'
27. 2026-09-07srcTowards a Biophysical Understanding of Hallucinogen Action
28. 2026-09-07srcSchedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I (Federal Register 2015-29026)
29. 2026-09-07srcUK Temporary Class Drug Order on NBOMe and Benzofuran (Circular 008/2013)
30. 2026-09-04issueIssued emergency
31. 2026-09-04issueIssued info_card
32. 2026-09-04issueIssued notice
33. 2026-06-04proposal30 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
34. 2026-06-04publicationPublication — backfill
35. 2026-05-08revisionRevision 1
36. 2026-05-08absenceSearched ClinicalTrials.gov for "25D-NBOMe NBOMe phenethylamine" — no results
37. 2026-05-08genGeneration — pipeline-v5 · with 4 morepipeline-v5
38. 2026-05-08rungeneration run

The same entries, as forms: six forms.